# Top 10 intervention extracts from small_cell_lung_NL_cleaned.json

=== Ranked Intervention 1 (Extract #19, Treatment) — Score: 9 ===
1 Row 1: Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de Richtlijnendatabase.|
Row 2: |
Row 3: Referenties|
Row 4: |
Row 5: 1 - von Pawel J, Schiller JH, Shepherd FA et al. Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer. J Clin Oncol 1999; 17(2):658-667.|
Row 6: 2 - Sculier JP, Lafitte JJ, Lecomte J et al. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Ann Oncol

=== Ranked Intervention 2 (Extract #21, Treatment) — Score: 8 ===
29-333.|
Row 12: 6 - Ando M, Kobayashi K, Yoshimura A et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 2004; 44(1):121-127.|
Row 13: 7 - Ardizzoni A, Manegold C, Debruyne C et al. European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer. Clin Cancer Res 2003; 9(1):143-150.|
Row 14: 8 - Castellano DE, Ciruelos E, Garcia-Giron C et al. Phase II trial of biweekly irinotecan plus

=== Ranked Intervention 3 (Extract #22, Treatment) — Score: 8 ===
lus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 2004; 44(1):121-127.|
Row 13: 7 - Ardizzoni A, Manegold C, Debruyne C et al. European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer. Clin Cancer Res 2003; 9(1):143-150.|
Row 14: 8 - Castellano DE, Ciruelos E, Garcia-Giron C et al. Phase II trial of biweekly irinotecan plus gemcitabine combination in refractory or relapsed small cell lung cancer (SCLC) [abstract]. Proc Am Soc Cl

=== Ranked Intervention 4 (Extract #1, Treatment) — Score: 7 ===
of MRI compared to CCT in patients with brain metastases. J
Neurooncol. 1999;44(3):275-81.
2 - Hochstenbag MM, Twijnstra A, Hofman P, Wouters EF, ten Velde GP. MR-imaging of the brain of neurologic asymptomatic
patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer. 2003
Nov;42(2):189-93.
3 - Seute T, Leffers P, ten Velde GP, Twijnstra A. Detection of brain metastases from small cell lung cancer: consequences of
changing imaging techniques (CT versus MRI). Cancer. 2008 Apr 15;112(8):1827-34
Uitgangsvraag
Wat zijn prognostische factoren bij patiën

=== Ranked Intervention 5 (Extract #11, Treatment) — Score: 7 ===
compared to CCT in patients with brain metastases. J Neurooncol. 1999;44(3):275-81.
Row 6: 2 - Hochstenbag MM, Twijnstra A, Hofman P, Wouters EF, ten Velde GP. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer. 2003 Nov;42(2):189-93.
Row 7: Nov;42(2):189-93.
Row 8: 3 - Seute T, Leffers P, ten Velde GP, Twijnstra A. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). Cancer. 2008 Apr 15;112(8):1827-34
Row 9: 4 - Bradley JD, D

=== Ranked Intervention 6 (Extract #36, Therapy) — Score: 7 ===
% en boven 60 Gy 53-96%. Deze resultaten moeten echter voorzichtig geïnterpreteerd worden, omdat de studies sterk varieerden met betrekking tot het bestraalde volume, de behandeltijd en het type en de sequentie van de chemotherapie.
Row 12: In een fase I studie die werd uitgevoerd door de Radiation Therapy Oncology Group (RTOG 97-12) bedroeg de maximaal tolereerbare bestralingsdosis 61,2 Gy in 5 weken, wanneer dit tegelijk werd toegediend met cisplatin-etoposide (2). Verschillende fase III studies hebben de timing (vroege vs late thoracale bestraling) en de volgorde van bestraling en chemotherapie (s

=== Ranked Intervention 7 (Extract #18, Treatment) — Score: 5 ===
Clin Oncol 1987; 23(11):1697-1699.|Eur J Cancer Clin Oncol 1987;||
Row 7: 3 - Vincent M, Evans B, Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 1988; 21(1):45-48.|||Cancer Chemother
Row 8: 4 - Collard P, Weynants P, Francis C et al. Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin. Thorax 1992; 47(5):369-371.|||
Row 9: 5 - Batist G, Ihde DC, Zabell A et al. Small-cell carcinoma of lung: reinduction therapy after late relapse. Ann Intern M

=== Ranked Intervention 8 (Extract #26, Treatment) — Score: 5 ===
of anorexia-cachexia.|Clin Opin Oncol 1999;11:255-260|
Row 2: 6||| Row 1: Clin oncol 1993;11:2043-9.
Row 2: 7 Row 1: 1|0 - Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer.||Br Med J 1984;288:27.||
Row 2: 1|1 - Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer.|Drugs 1998;55:675–688.|||
Row 3: 1||||| Row 1: 1|3 - Mantovani G, Maccio A, Massa E, et al. Managing cancer-related anorexia / cachexia.||||Drugs 2001;61:499–514.|||
Row 2: 1|4 - Nelson KA. The cancer anorexia-cachexia syndrome.|Semin Oncol 2000;27:64–68.||||||
R

=== Ranked Intervention 9 (Extract #28, Treatment) — Score: 5 ===
era E. Anorexia, cachexia and nutrition.|B Med J 1997;315:1219-1222|.|
Row 2: 4||||Curr Clin Nutr Metab Care 1999 Row 1: 1|0 - Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer.||Br Med J 1984;288:2|
Row 2: 1|1 - Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer.|Drugs 1998;55:675–688.||
Row 3: 1|||| Row 1: 1|3 - Mantovani G, Maccio A, Massa E, et al. Managing cancer-related anorexia / cachexia.||||Drugs 2001;61:499–514.|||
Row 2: 1|4 - Nelson KA. The cancer anorexia-cachexia syndrome.|Semin Oncol 2000;27:64–68.||||||
Row

=== Ranked Intervention 10 (Extract #30, Drug) — Score: 5 ===
drome of anorexia-cachexia.|Clin Opin Oncol 1999;11:255-260|
Row 2: 6||| Row 1: Clin oncol 1993;11:2043-9.
Row 2: 7 Row 1: 1|0 - Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer.||Br Med J 1984;288:27.||
Row 2: 1|1 - Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer.|Drugs 1998;55:675–688.|||
Row 3: 1||||| Row 1: 1|3 - Mantovani G, Maccio A, Massa E, et al. Managing cancer-related anorexia / cachexia.||||Drugs 2001;61:499–514.|||
Row 2: 1|4 - Nelson KA. The cancer anorexia-cachexia syndrome.|Semin Oncol 2000;27:64–6

